araag2/HINT huggingface dataset:
Clinical trial NCT00259090 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: fulvestrant, anastrazole
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H], CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal women.

          -  Biopsy confirmation of primary breast cancer.

          -  Oestrogen receptor positive tumour.

          -  Fit for surgery within one month.

          -  Written informed consent to participate in the study

        Exclusion Criteria:

          -  Previous treatment with any anti-hormonal therapy for breast cancer.

          -  Previous radiotherapy to the primary tumour.

          -  Previous chemotherapy for the primary tumour.
Clinical trial NCT01237665 (phase 2, status: unknown status)
Conditions: rectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: ixo regimen
SMILES: CCO
Eligibility criteria:

        Inclusion Criteria:

        General

          -  Pathologically confirmed rectal adenocarcinoma

          -  T3 or T4 or N1 (node ≥1 cm on short axis) adenocarcinoma of the rectum.

          -  ECOG performance status equal or less than 1

          -  Male and female patients, aged ≥ 18 years and ≤ 80 years

          -  Written informed consent

          -  Adequate haematological, liver, renal function

        Resectability

          -  Patients categorized as having resectable locally advanced cancer

          -  Favorable general condition

        Exclusion Criteria:

        Resectability

          -  Diagnosis of metastatic disease

          -  Clear indication of involvement of pelvic wall(s), on imaging.

          -  Peritoneal carcinomatosis, portal vein occlusion, ascites, non-regional lymph nodes

          -  Histology other than adenocarcinoma

          -  Obstructed rectal carcinoma without defunctionalizing colostomy

        Prior treatment

          -  Previously undergone treatment for this disease

          -  Prior chemotherapy for colorectal cancer

          -  Prior chemotherapy for other malignancies in past 12 months

          -  Prior radiotherapy other than skin cancer

          -  Concomitant use of St John's Wort

          -  Treatment with any other investigational agent

          -  Current use of full-dose of warfarin for therapeutic

        Other conditions

          -  Confirmed or suspected brain metastases

          -  History or evidence of CNS disease

          -  Past or current history of other malignancies

          -  Clinically significant cardiovascular disease

          -  Evidence of bleeding diathesis or coagulopathy

          -  Known hypersensitivity to any of the study drugs

          -  Serious, non-healing wound, ulcer or bone fracture

          -  Major surgical procedure or significant traumatic injury within 28 days prior to
             treatment

          -  Disease or condition that contraindicates the use of an investigational drug

          -  Life expectancy less than 5 years

          -  Inability or unwillingness to comply with the protocol

          -  Neuropathy ≥ Gr.2

          -  History of ulcerative colitis or Crohn's disease

          -  Pelvic abscess or perforated pelvic carcinoma

        Pregnancy / Contraception

          -  Pregnancy or lactation

          -  Positive serum pregnancy test within 7 days of starting study treatment
Clinical trial NCT00295425 (phase 2, status: unknown status)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: cyclosporine a versus mycophenolate mofetil for psoriasis
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  moderate-to-severe psoriasis (PASI Score equal and greated 10)

          -  written informed consent

          -  for female patients effective birth control

        Exclusion Criteria:

          -  psoriasis arthritis

          -  psoriasis palmo-plantaris

          -  erythrodermic psoriasis

          -  drug-induced psoriasis

          -  pregnancy

          -  previous treatment with cyclosporine A or mycophenolate mofetil

          -  pregnancy

          -  reduced liver function

          -  high blood pressure

          -  reduced kidney function

          -  severe viral or bacterial infection

          -  2 weeks before or after vaccinations

          -  innate or acquired immunodeficiency

          -  severe neurologic or psychiatric symptoms

          -  participation in other trials

          -  other reasons voiced by the treating physician
Clinical trial NCT01277081 (phase 2, status: completed)
Conditions: common cold
ICD codes: J00, T48.5X6S, T48.5X3S, T48.5X4S, T48.5X5S, T48.5X6A, T48.5X6D
Drugs: paracetamol hot drink, paracetamol tablets
SMILES: CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O, CC(=O)NC1=CC=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Symptoms of the common cold of no more than 120 hours duration

          -  Self-rating congestion of at least moderate severity

          -  Suffering from at least four symptoms of common cold or flu
Clinical trial NCT00607997 (phase 2, status: completed)
Conditions: leukemia, acute disease, acute myeloid leukemia, nonlymphocytic leukemia, myelodysplastic syndromes
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60, D46.9, D46.C, D46.Z
Drugs: vosaroxin
SMILES: CN[C@H]1CN(C[C@@H]1OC)C1=CC=C2C(=O)C(=CN(C3=NC=CS3)C2=N1)C(O)=O
Eligibility criteria:

        Key Inclusion Criteria:

          1. At least 60 years of age and diagnosis of previously untreated AML (either de novo or
             from an antecedent hematologic disorder or therapy related AML)

          2. At least 20% blasts by BM biopsy or aspirate

          3. ECOG performance status of 0,1,or 2

          4. Adequate cardiac, renal and liver function

        Key Exclusion Criteria:

          1. Uncontrolled DIC

          2. Active central nervous system involvement by AML

          3. Requiring hemodialysis or peritoneal dialysis

          4. Some prior history of heart attack or stroke (depending on how long ago the event
             occurred)
Clinical trial NCT00078975 (phase 2, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: gemcitabine hydrochloride, triapine
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, NC(=S)N\N=C\C1=C(N)C=CC=N1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed pancreatic adenocarcinoma

               -  Recurrent, unresectable, or metastatic disease

          -  At least 1 unidimensionally measurable lesion

               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan

               -  Prior radiation field must not have encompassed the only site of measurable
                  disease

          -  No known brain metastases

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-2 OR

          -  Karnofsky 60-100%

        Life expectancy

          -  More than 12 weeks

        Hematopoietic

          -  WBC ≥ 3,000/mm^3

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  No G6PD deficiency

        Hepatic

          -  Bilirubin ≤ 1.5 times normal

          -  AST and ALT ≤ 2.5 times upper limit of normal

        Renal

          -  Creatinine ≤ 1.5 times normal OR

          -  Creatinine clearance ≥ 60 mL/min

        Cardiovascular

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

          -  No symptomatic congestive heart failure

        Pulmonary

          -  No severe pulmonary disease

          -  No dyspnea at rest

          -  No dependence on supplemental oxygen use

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 3 months after study
             treatment

          -  No prior allergic reaction attributed to compounds of similar chemical or biological
             composition to study drugs

          -  No ongoing or active infection

          -  No psychiatric illness or social situation that would preclude study compliance

          -  No other concurrent uncontrolled illness that would preclude study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy except fluorouracil given as adjuvant therapy OR as a
             radiosensitizer during radiotherapy

          -  More than 4 weeks since prior adjuvant fluorouracil therapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  See Disease Characteristics

          -  See Chemotherapy

          -  More than 4 weeks since prior radiotherapy and recovered

        Surgery

          -  Not specified

        Other

          -  No other concurrent investigational agents

          -  No other concurrent anticancer therapy

          -  No concurrent combination antiretroviral therapy for HIV-positive patients
Clinical trial NCT00057226 (phase 2, status: completed)
Conditions: depressive disorder, major
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: radafaxine
SMILES: C[C@@H]1NC(C)(C)CO[C@@]1(O)C1=CC=CC(Cl)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Major Depressive Disorder (MDD)

          -  Duration of current depressive episode 12 weeks - 24 months

          -  Patients can read and write at a level sufficient to provide a signed consent

          -  If female, patients must be practicing an acceptable method of birth control

        Exclusion Criteria:

          -  Patients have other psychiatric disorders that would affect patient's response to
             treatment

          -  Patients have not responded to two or more adequate courses of antidepressant therapy

          -  Patients cannot be currently abusing illicit drugs or alcohol

          -  Patients are not currently receiving psychotherapy

          -  Patients have received electroconvulsive therapy within 6 months prior to screening

          -  Patients are pregnant or lactating
Clinical trial NCT00263354 (phase 2, status: completed)
Conditions: stomach neoplasms
ICD codes: D13.1, C16.9, C16.1, C16.2, D37.1, C16.8, C16.5
Drugs: oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  ECOG performance status of 0-2.

          -  Histologically proven gastric or gastro-esophageal junction adenocarcinoma.

          -  At least unidimensional measurable disease. If a unique metastasis constitutes the
             only disease sign, it requires histological confirmation.

          -  First line locally unresectable or metastatic gastric cancer.

          -  Relapsing gastric cancer after local and/or systemic treatment with a post-surgical
             period of at least 4 weeks, a post-adjuvant or neoadjuvant chemoradiotherapy period of
             at least 6 months.

          -  Serum bilirubin < 2 mg/dl

          -  Serum creatinine < or = 2 mg/dl

          -  Hemoglobin > or = 10 g/dl

          -  Absolute neutrophil count > or = 2000/dl

          -  Platelet count >or = 100, 000/dl

          -  AST/ALT < or = 2.5 time-fold the institutional normal upper limit

          -  Alkaline phosphatase < or = 5 time-fold the institutional normal upper limit

          -  Imagenological evaluation of the patient at least 2 weeks prior to the drug infusion

          -  Laboratory tests at least 1 week prior to the first infusion

          -  Patient available for follow up and able to answer to the quality of life
             questionnaire

        Exclusion Criteria:

          -  Symptomatic sensorial peripheral neuropathy

          -  Uncontrolled concomitant disease

          -  Another malignant neoplastic disease diagnosed within the previous 5 years to the
             diagnosis of advanced or metastatic gastric cancer, with the exception of 'in situ'
             cervix carcinoma or non-melanoma skin cancer

          -  Concomitant antitumoral treatment

          -  Cerebral metastases

          -  Unstable heart disease, even though in treatment

          -  Myocardial infarction within the last 6 months

          -  Radiotherapy within the last 6 weeks, surgery within the last 4 weeks, or chemotherapy
             within the last 6 months.

          -  Pregnancy or nursing ( or women in reproductive life without adequate contraception)

          -  Significant neurological or psychiatric disorders.
Clinical trial NCT00640185 (phase 2, status: completed)
Conditions: attention-deficit/hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: abt-089, placebo
SMILES: CC1=C(OC[C@@H]2CCCN2)C=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have voluntarily signed an informed consent form.

          -  Meet diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD) based on
             detailed evaluation and interview with subject.

          -  Subject is generally in good health based on medical history, physical examination,
             clinical lab tests and ECG.

          -  Female subjects of child-bearing potential must have a negative urine pregnancy test
             at screening and baseline and agree to comply with applicable contraceptive
             requirements.

          -  Male subjects must agree to comply with applicable contraceptive requirements.

          -  Subject is able to keep required appointments for clinic visits and all tests,
             including blood draws and examinations.

        Exclusion Criteria:

          -  Subject has a current or past diagnosis of schizoaffective disorder, schizophrenia,
             obsessive-compulsive disorder, drug-induced psychosis, bipolar disorder, psychotic
             disorder.

          -  Current diagnosis of major depressive disorder, generalized anxiety disorder, PTSD or
             has a sleep disorder requiring treatment of any kind.

          -  Subject has a history of, or ongoing, serious medical problem.

          -  Subject has a history of significant allergic reaction to any drug.

          -  Subject is planning to begin any type of behavioral or psychotherapy for treatment of
             ADHD.

          -  Subject requires ongoing treatment with any psychiatric medication.
Clinical trial NCT00489489 (phase 2, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: teriflunomide, placebo (for teriflunomide), interferon-β
SMILES: C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Definite MS diagnosis according to McDonald's criteria;

          -  Relapsing clinical course, with or without progression;

          -  Expanded Disability Status Scale [EDSS] less or equal to 5.5 (ambulatory);

          -  Stable dose of IFN-β for at least 26 weeks prior to the screening visit;

          -  No onset of MS relapse in the preceding 60 days prior to randomization;

          -  Clinically stable for 4 weeks prior to randomization.

        Exclusion Criteria:

          -  Other chronic disease of the immune system, liver function impairment or chronic
             pancreatic disease;

          -  Pregnant or nursing woman;

          -  Alcohol or drug abuse;

          -  Use of cladribine, mitoxantrone, or other immunosuppressant agents such as
             azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before
             enrollment;

          -  Human immunodeficiency virus [HIV] positive status;

          -  Any known condition or circumstance that would prevent in the investigator's opinion
             compliance or completion of the study.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00319865 (phase 2, status: unknown status)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: velcade, thalidomide, adriamycin, dexamethasone
SMILES: CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl, CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with multiple myeloma who relapsed after at least 1 lines of therapy
             including high dose thearapy with autologous stem cell transplantation and
             chemotherapy.

          -  Presence of measureble disease : serum M-protein > 1g/dL or urine M-protein >
             400mg/day

          -  Age < 75

          -  Performance status </= ECOG 2

          -  Expected survival > 6 months

          -  who signs the informed consent

        Exclusion Criteria:

          -  known hypersensitivity to thalidomide or dexamethasone

          -  known refractoriness to thalidomide + dexamethasone

          -  Previous Velcade therapy

          -  Sepsis

          -  Woman in reproductive age

          -  Serum creatinine > 2 mg/dL ; 24 hour creatinine clearance < 30 ml/min; past medical
             history of kidney transplatation

          -  Peripheral neuropathy >/= grade 2

          -  Recurrent DVT or pulmonary embolism

          -  Cardiac ejection fraction <0.5 : Severe conduction disorder

          -  Hepatic dysfunction (AST or ALT ≥ x 5 upper normal) or active hepatitis

          -  Active ulcers in gastrofiberscope
Clinical trial NCT01318083 (phase 2/phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: alogliptin and glimepiride, alogliptin and glimepiride, glimepiride
SMILES: [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Had been taking a sulfonylurea for at least 4 weeks prior to the initiation of the
             observation period (Week -12).

          2. Had been taking glimepiride at a stable dose regimen (1, 2, 3 or 4 mg/day, once or
             twice daily in the morning or in the morning and evening, before or after meal) for at
             least 12 weeks prior to the initiation of the treatment period (Week 0).

          3. Had glycosylated hemoglobin (HbA1c) of 7.0% or more and below 10.0% at 8 weeks after
             the initiation of the observation period (Week -4).

          4. Had an HbA1c difference between 4 weeks after the initiation of the observation period
             (Week -8) and 8 weeks after the initiation of the observation period (Week -4) being
             within 10.0%* of the value at 4 weeks after the initiation of the observation period
             (Week -8) (*rounded off to the first decimal place).

          5. Was receiving specific diet and exercise (if any) therapies during the observation
             period.

        Exclusion Criteria:

        1. Had taken other diabetic medications than glimepiride within 12 weeks before the
        initiation of the treatment period (Week 0).
Clinical trial NCT00275561 (phase 2, status: completed)
Conditions: eosinophilic esophagitis
ICD codes: K20.0
Drugs: fluticasone, placebo
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  > 20 eosinophils / hpf on biopsies from mid esophagus (hpf = high-powered field)

          -  Abnormal dysphagia questionnaire (question 1a "yes", question 1c > "moderate" and
             question 2 > "less than once a week") on Mayo Dysphagia Questionnaire.

        Exclusion Criteria:

          -  Clinical evidence of infectious process potentially contributing to dysphagia (e.g.,
             candidiasis, cytomegalovirus, herpes)

          -  Systemic or topical steroid therapy for any reason over the past 3 months

          -  Previous steroid treatment for Eosinophilic Esophagitis

          -  Intolerance to steroid therapy in the past

          -  Other cause of dysphagia identified at endoscopy (e.g., reflux esophagitis, stricture,
             web, ring, achalasia, esophageal neoplasm)

          -  Dilatation of esophagus at time of index endoscopy
Clinical trial NCT00378755 (phase 2, status: unknown status)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: velcade
SMILES: CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl
Eligibility criteria:

        Inclusion Criteria:

          -  1.Previously untreated newly diagnosed patients with MM (stage II-III) 2.Age < 65
             3.Eastern Cooperative Oncology Group Performance Status 0-1 4.EF > 50%, FVC and FEV >
             50%, DLCO >50% 5.Platelet count ≥ 100 x 109/L (pretreatment platelet transfusion is
             not allowed, while transfusion during the treatment is permitted), hemoglobin ≥ 8 g/dL
             (≥ 4.96 mol/L), Prior RBC transfusion or recombinant human erythropoietin use is
             allowed), absolute neutrophil count (ANC) ≥ 1.0 x 109/L 6.Adequate liver function
             (bilirubin < UNL(Upper Normal Limit) x 2 and ALT/AST < UNL x 3) 7.Adequate renal
             function (serum creatinine < UNL x 1.5 or creatine clearance > 60 ml/min) 8.Signed the
             informed consent, have the will and ability to follow the protocol

        Exclusion Criteria:

          -  1. History of allergic reaction attributable to compounds containing boron or mannitol
             2. Known hypersensitivity to thalidomide or dexamethasone 3. Peripheral neuropathy or
             neuropathic pain Grade 2 or higher as defined by NCI CTCAE version 3 4. Uncontrolled
             or severe cardiovascular disease, including MI within 6 months of enrollment, New York
             Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina,
             clinically significant pericardial disease, or cardiac amyloidosis 5. Acute severe
             infection requiring antibiotic therapy 6. Previous cancer history (except in situ
             carcinoma of cervix or basal cell cancer of skin) 7. Pregnancy or breastfeeding 8.
             Active ulcer detected by gastroscopy (gastroscopy is not routine in all patients, only
             to patients with symptoms of ulcer disease and/or history of previous ulcer therapy
             and/or physician's discretion) 9. Previous renal transplantation 10. Recurrent deep
             vein thrombosis or pulmonary embolism 11. Uncontrolled diabetes mellitus 12. Receipt
             of extensive radiation therapy within 4 weeks ((Extensive means RT to more than 2
             anatomic sites).